132 related articles for article (PubMed ID: 22105164)
1. A new medical therapy for Cushing disease?
Wondisford FE
J Clin Invest; 2011 Dec; 121(12):4621-3. PubMed ID: 22105164
[TBL] [Abstract][Full Text] [Related]
2. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.
Fukuoka H; Cooper O; Ben-Shlomo A; Mamelak A; Ren SG; Bruyette D; Melmed S
J Clin Invest; 2011 Dec; 121(12):4712-21. PubMed ID: 22105169
[TBL] [Abstract][Full Text] [Related]
3. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
4. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
[TBL] [Abstract][Full Text] [Related]
5. Advances in the medical treatment of Cushing's syndrome.
Feelders RA; Newell-Price J; Pivonello R; Nieman LK; Hofland LJ; Lacroix A
Lancet Diabetes Endocrinol; 2019 Apr; 7(4):300-312. PubMed ID: 30033041
[TBL] [Abstract][Full Text] [Related]
6. New potential targets for treatment of Cushing's disease: epithelial growth factor receptor and cyclin-dependent kinases.
Fukuoka H
Pituitary; 2015 Apr; 18(2):274-8. PubMed ID: 25612787
[TBL] [Abstract][Full Text] [Related]
7. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Jackman D; Pao W; Riely GJ; Engelman JA; Kris MG; Jänne PA; Lynch T; Johnson BE; Miller VA
J Clin Oncol; 2010 Jan; 28(2):357-60. PubMed ID: 19949011
[TBL] [Abstract][Full Text] [Related]
8. [The predictive value of EGFR status in non-small cell lung cancer patients treated with EGFR-TKIs].
Wang Y; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):375-9. PubMed ID: 20677568
[TBL] [Abstract][Full Text] [Related]
9. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
Irwin ME; Mueller KL; Bohin N; Ge Y; Boerner JL
J Cell Physiol; 2011 Sep; 226(9):2316-28. PubMed ID: 21660955
[TBL] [Abstract][Full Text] [Related]
10. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
[TBL] [Abstract][Full Text] [Related]
11. [Research progress on resistance mechanisms of epidermal growth factor receptor
tyrosine kinase inhibitors in non-small cell lung cancer].
Li Y; Song L
Zhongguo Fei Ai Za Zhi; 2012 Feb; 15(2):106-11. PubMed ID: 22336239
[TBL] [Abstract][Full Text] [Related]
12. Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.
Watanabe S; Tanaka J; Ota T; Kondo R; Tanaka H; Kagamu H; Ichikawa K; Koshio J; Baba J; Miyabayashi T; Narita I; Yoshizawa H
BMC Cancer; 2011 Jan; 11():1. PubMed ID: 21194487
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers.
Fukui T; Mitsudomi T
Gen Thorac Cardiovasc Surg; 2008 Mar; 56(3):97-103. PubMed ID: 18340507
[TBL] [Abstract][Full Text] [Related]
14. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
Costa DB; Halmos B; Kumar A; Schumer ST; Huberman MS; Boggon TJ; Tenen DG; Kobayashi S
PLoS Med; 2007 Oct; 4(10):1669-79; discussion 1680. PubMed ID: 17973572
[TBL] [Abstract][Full Text] [Related]
15. Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside.
Ben-Shlomo A; Cooper O
Curr Opin Endocrinol Diabetes Obes; 2017 Aug; 24(4):301-305. PubMed ID: 28520590
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse.
Shaw PH; Maughan TS; Clarke AR
Br J Cancer; 2011 Aug; 105(5):649-57. PubMed ID: 21811251
[TBL] [Abstract][Full Text] [Related]
17. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
[TBL] [Abstract][Full Text] [Related]
18. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.
Chiu CH; Yang CT; Shih JY; Huang MS; Su WC; Lai RS; Wang CC; Hsiao SH; Lin YC; Ho CL; Hsia TC; Wu MF; Lai CL; Lee KY; Lin CB; Yu-Wung Yeh D; Chuang CY; Chang FK; Tsai CM; Perng RP; Chih-Hsin Yang J
J Thorac Oncol; 2015 May; 10(5):793-799. PubMed ID: 25668120
[TBL] [Abstract][Full Text] [Related]
19. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
Guix M; Faber AC; Wang SE; Olivares MG; Song Y; Qu S; Rinehart C; Seidel B; Yee D; Arteaga CL; Engelman JA
J Clin Invest; 2008 Jul; 118(7):2609-19. PubMed ID: 18568074
[TBL] [Abstract][Full Text] [Related]
20. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
